Charles Lickfold - Catalent Senior Vice President, Chief Information Officer
President
Charles Lickfold is Senior Vice President, Chief Information Officer of Catalent since 2020.
| Age | 50 |
| Tenure | 5 years |
| Phone | 732 537 6200 |
| Web | https://www.catalent.com |
Charles Lickfold Latest Insider Activity
Tracking and analyzing the buying and selling activities of Charles Lickfold against Catalent stock is an integral part of due diligence when investing in Catalent. Charles Lickfold insider activity provides valuable insight into whether Catalent is net buyers or sellers over its current business cycle. Note, Catalent insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalent'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Charles Lickfold over three months ago Disposition of 637 shares by Charles Lickfold of Catalent subject to Rule 16b-3 |
Catalent Management Efficiency
Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Catalent currently holds 4.92 B in liabilities with Debt to Equity (D/E) ratio of 0.9, which is about average as compared to similar companies. Catalent has a current ratio of 2.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Catalent's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Aileen RuffPatry | West Pharmaceutical Services | N/A | |
| Joseph LaPlume | Charles River Laboratories | 50 | |
| Walter Staub | IQVIA Holdings | 57 | |
| Eric Resnick | West Pharmaceutical Services | 55 | |
| George Miller | West Pharmaceutical Services | 64 | |
| Silji Abraham | West Pharmaceutical Services | 53 | |
| Nilton Paletta | IQVIA Holdings | N/A | |
| Bhavik Patel | IQVIA Holdings | 45 | |
| Andy Polywacz | West Pharmaceutical Services | N/A | |
| Timothy Ernst | Bio Rad Laboratories | 64 | |
| Ronald Hutton | Bio Rad Laboratories | 62 | |
| Matthew James | Teleflex Incorporated | N/A | |
| James Leyden | Teleflex Incorporated | 52 | |
| Kevin Knightly | IQVIA Holdings | 63 | |
| Richard III | IQVIA Holdings | 62 | |
| David Smith | Charles River Laboratories | 58 | |
| Ronald Bruehlman | IQVIA Holdings | 64 | |
| James Ferguson | Teleflex Incorporated | N/A | |
| Ilan Daskal | Bio Rad Laboratories | 58 | |
| Annette Tumolo | Bio Rad Laboratories | 65 | |
| Birgit Girshick | Charles River Laboratories | 55 | |
Management Performance
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0018 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
| Paul Surdez, Vice Relations | ||
| Joseph JD, General VP | ||
| Tom PEng, President Delivery | ||
| Trish Hunt, President Health | ||
| Peter Zippelius, Independent Director | ||
| David McErlane, Group Segment | ||
| Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
| Michael Hatzfeld, VP Officer | ||
| Kay Schmidt, Senior Vice President - Technical Operations | ||
| Karen Santiago, VP Office | ||
| Jonathan Arnold, President - Oral & Specialty Delivery | ||
| Ricky Hopson, Division President | ||
| John MBA, Executive Board | ||
| John Chiminski, Chairman of the Board, Chief Executive Officer | ||
| Donald Morel, Independent Director | ||
| John Greisch, Independent Director | ||
| Gregory Lucier, Independent Director | ||
| Rolf Classon, Independent Director | ||
| Michael Barber, Independent Director | ||
| Steven Esq, Corp VP | ||
| Karen Flynn, President - Biologics and Chief Commercial Officer | ||
| Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
| Matti Masanovich, Senior CFO | ||
| Julien Meissonnier, VP Officer | ||
| Christa Kreuzburg, Independent Director | ||
| Lisa Evoli, Senior Officer | ||
| Madhavan Balachandran, Independent Director | ||
| J Carroll, Independent Director | ||
| Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
| Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
| Alessandro Maselli, Senior Vice President - Global Operations | ||
| Dejan Lamesic, Head Development | ||
| Ricci Whitlow, President - Clinical Supply Services | ||
| Charles Lickfold, Senior Vice President, Chief Information Officer | ||
| Aristippos Gennadios, President - Softgel & Oral Technologies | ||
| Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
| Jack Stahl, Lead Independent Director | ||
| Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
| Rosemary Crane, Independent Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.11 | |||
| Return On Asset | -0.0018 | |||
| Profit Margin | (0.09) % | |||
| Operating Margin | (0.07) % | |||
| Current Valuation | 16.13 B | |||
| Shares Outstanding | 181.51 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Shares Owned By Institutions | 87.80 % | |||
| Number Of Shares Shorted | 14.74 M | |||
| Price To Earning | 17.80 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Consideration for investing in Catalent Stock
If you are still planning to invest in Catalent check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalent's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |